A draft guideline by the United States Preventive Services Task Force recommends that colorectal cancer screening should begin five years earlier—at age 45 for average-risk individuals.
A study by researchers at Thomas Jefferson University and Sidney Kimmel Cancer Center – Jefferson Health demonstrates that although Black patients are now more likely to receive the most effective treatment in non-small cell lung cancer than a decade ago, disparities persist.
Winship Cancer Institute of Emory University researchers found that treatment based on advanced molecular imaging can improve disease-free survival rates for men with prostate cancer with recurring cancer.
The New York Proton Center is joining the first national randomized clinical trial to evaluate the efficacy of proton therapy compared to traditional radiotherapy for patients with locally advanced breast cancer.
FDA has approved FoundationOne Liquid CDx for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies.
The American Association for Cancer Research said its 2021 meeting will be virtual.
C. Ola Landgren was named director of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center of the University of Miami.
Neuro-oncologist Ingo K. Mellinghoff was appointed chair of the Department of Neurology at Memorial Sloan Kettering Cancer Center.
Beth Gaffney was named vice president of U.S. and Global Business Development at the National Clinical Trials Network.
The Reagan-Udall Foundation for the FDA has received $250,000 in funding from the Rockefeller Foundation to support the COVID-19 Diagnostics Evidence Accelerator launched earlier this year in collaboration with Friends of Cancer Research.
